


ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

February 28, 2021



COVID-19 Work Group activities – February 2021

- COVID-19 Vaccine Work Group meets weekly
- Topics covered:
 - Overview of Adenovirus vector vaccines
 - Clinical development program for Ad26.COV.2 (Janssen) COVID-19 vaccine
 - GRADE/EtR for Janssen COVID-19 vaccine
 - Considerations for the use of COVID-19 vaccines
 - Safety updates

Update

- On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Janssen COVID-19 vaccine for the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age and older

Today's Agenda

Sunday, February 28

- **Overview of Janssen's single dose COVID-19 vaccine, Ad26.COV2.S**
Dr. Macaya Douoguih (Janssen Pharmaceuticals Companies of Johnson & Johnson)
- **GRADE: Janssen COVID-19 vaccine**
Dr. Julia Gargano (CDC)
- **Evidence to Recommendation Framework: Janssen COVID-19 vaccine**
Dr. Sara Oliver (CDC)
- **Public Comment**
- **Discussion**
- **VOTE:**
Janssen COVID-19 vaccine

Tomorrow's Agenda

Monday, March 1

- **Implementation considerations for COVID-19 vaccines**
Dr. Kathleen Dooling (CDC)
- **Clinical considerations for use of COVID-19 vaccines**
Ms. Jessica MacNeil (CDC)
- **Vaccine Safety Technical Subgroup (VaST) introduction**
Dr. Grace Lee (ACIP, VaST Co-chair)
- **COVID-19 Vaccine Safety Update**
Dr. Tom Shimabukuro (CDC)
- **VaST assessment of safety data**
Dr. Grace Lee (ACIP, VaST Co-chair)
- **Emerging SARS-CoV-2 variants**
Dr. Heather Scobie (CDC)

Work group members

ACIP members

- Beth Bell (chair)
- Matthew Daley
- Grace Lee
- Jose Romero
- Keipp Talbot

Ex-officio/government members

- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Uzo Chukwuma
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

CDC Co-leads

- Kathleen Dooling
- Sara Oliver

Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett (primary), Christine Hahn (alternate)
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

Liaisons, cont’d


- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: Marci Drees

Consultants

- Ed Belongia
- Kathy Kinlaw
- Dayna Matthew
- Kathleen Neuzil
- Stanley Perlman
- Peter Szilagyi

CDC participants

- Amy Blaine
- Doug Campos-Outcalt
- Mary Chamberland
- Thomas Clark
- Amanda Cohn
- Jean Cox-Ganser
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Susan Goldstein
- Sam Graitcer
- Lisa Grohskopf
- Julie Garon
- Stephen Hadler
- Rita Helfand
- Susan Hiers
- Terri Hyde
- Cynthia Jorgensen
- Erin Kennedy
- Sarah Kidd
- Ram Koppaka
- Nicole Lindsey
- Ruth Link-Gelles
- Jessica MacNeil
- Lauri Markowitz
- Mona Marin
- Sarah Mbaeyi
- Nancy Messonnier
- Rebecca Morgan
- Titilope Oduyebo
- Anita Patel
- Janell Routh
- Stephanie Schrag
- Heather Scobie
- Edwin Shanley
- Tom Shimabukuro
- Heidi Soeters
- Mark Sotir
- Stephanie Thomas
- Natalie Thornburg
- Jennifer Verani
- Megan Wallace
- Annemarie Wasley
- Cindy Weinbaum
- Melinda Wharton
- Yon Yu



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

